Intellia Therapeutics
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Intellia Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Intellia Therapeutics: 3 sponsored US clinical trials, none currently recruiting.
Intellia Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, with 1 trials.
Upper-quartile sponsor footprint
Intellia Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
NCT05066165
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
How the Intellia Therapeutics archive is shaped
3 indexed studies, none listed as recruiting (0% open).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Intellia Therapeutics: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Intellia Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Intellia Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Intellia Therapeutics or any single study.
- None of Intellia Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy is the condition Intellia Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transthyretin Amyloidosis (ATTR) With Cardiomyopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Intellia Therapeutics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.